CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

Additional Metadata
Persistent URL	doi.org/10.1186/1471-2407-10-247, hdl.handle.net/1765/81766
Journal	BMC Cancer
Organisation	Department of Medical Oncology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Dietrich, D., Krispin, M., Dietrich, J., Fassbender, A., Lewin, J., Harbeck, N., Schmitt, M., Eppenberger-Castori, S., Vuaroqueaux, V., Spyratos, F., Foekens, J., Lesche, R.& Martens, J. (2010). CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients. BMC Cancer, 10.https://doi.org/10.1186/1471-2407-10-247

Publication